Clinical research in cardiology : official journal of the German Cardiac Society · 2026
Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Los Jonathan, Mensink Frans B, Reda Morsy Mohamed M, Nishimiya Kensuke, Oemrawsingh Rohit M, IJsselmuiden Alexander J J, Meuwissen Martijn, Cheng Jin M, Rai Himanshu, Ten Cate Tim J F, Camaro Cyril, Damman Peter, van Nunen Lokien X, Dimitriu-Leen Aukelien C, van Wely Marleen H, Cetinyurek-Yavuz Aysun, Byrne Robert A, van Royen Niels, van Geuns Robert-Jan M
Аннотация
AIMS: The aim of this study was to evaluate the short-term potential of very-high-intensity lipid-lowering therapy on lesion-level atheroma burden.
METHODS: The investigator-initiated, double-blind, placebo-controlled FITTER trial (enrollment November 2020 to August 2023) randomized patients presenting with acute coronary syndrome (ACS) and relevant non-culprit coronary artery disease (fractional flow reserve: 0.67-0.85) to receive either evolocumab or placebo for 12 weeks in addition to high-intensity statin therapy to evaluate the short-term potential of lipid-lowering therapy on non-culprit plaque features. Present lesion-level analysis assessed the effects on coronary segments with advanced atherosclerotic plaque characteristics with increased cardiovascular risk and includes all patients who underwent successful serial intravascular ultrasound-near-infrared spectroscopy (IVUS-NIRS) imaging and with presence of IVUS-derived atherosclerotic lesions.
RESULTS: A total of 126 lesions were identified in 85 patients (mean age 65.1 ± 8.3, 18.8% female), of which 65 lesions were found in the evolocumab group (44 patients) and 61 in the placebo group (41 patients). Compared to placebo, patients treated with evolocumab did not demonstrate significant reductions in maximum lipid core index within any 4 mm segment (maxLCBI4mm, between-group difference, -9.6 [95% CI, -52.8 to 33.6]; p = 0.7) or percent atheroma volume (PAV, between-group difference, 1.0% [95% CI, -1.3 to 3.2]; p = 0.4). However, an overall reduction in maxLCBI4mm (overall change, -54.2 [95% CI, -89.6 to -18.7]; p = 0.003) and PAV (overall change, -2.0% [95% CI, -3.9 to -0.1]; p = 0.04) was observed.
CONCLUSIONS: Compared with placebo, the addition of evolocumab did not yield incremental improvements in lesion-level atheroma burden in the first 12 weeks after ACS. However, in the pooled analysis, significant short-term reductions in atheroma volume and plaque lipid content were observed.
TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT04141579.
METHODS: The investigator-initiated, double-blind, placebo-controlled FITTER trial (enrollment November 2020 to August 2023) randomized patients presenting with acute coronary syndrome (ACS) and relevant non-culprit coronary artery disease (fractional flow reserve: 0.67-0.85) to receive either evolocumab or placebo for 12 weeks in addition to high-intensity statin therapy to evaluate the short-term potential of lipid-lowering therapy on non-culprit plaque features. Present lesion-level analysis assessed the effects on coronary segments with advanced atherosclerotic plaque characteristics with increased cardiovascular risk and includes all patients who underwent successful serial intravascular ultrasound-near-infrared spectroscopy (IVUS-NIRS) imaging and with presence of IVUS-derived atherosclerotic lesions.
RESULTS: A total of 126 lesions were identified in 85 patients (mean age 65.1 ± 8.3, 18.8% female), of which 65 lesions were found in the evolocumab group (44 patients) and 61 in the placebo group (41 patients). Compared to placebo, patients treated with evolocumab did not demonstrate significant reductions in maximum lipid core index within any 4 mm segment (maxLCBI4mm, between-group difference, -9.6 [95% CI, -52.8 to 33.6]; p = 0.7) or percent atheroma volume (PAV, between-group difference, 1.0% [95% CI, -1.3 to 3.2]; p = 0.4). However, an overall reduction in maxLCBI4mm (overall change, -54.2 [95% CI, -89.6 to -18.7]; p = 0.003) and PAV (overall change, -2.0% [95% CI, -3.9 to -0.1]; p = 0.04) was observed.
CONCLUSIONS: Compared with placebo, the addition of evolocumab did not yield incremental improvements in lesion-level atheroma burden in the first 12 weeks after ACS. However, in the pooled analysis, significant short-term reductions in atheroma volume and plaque lipid content were observed.
TRIAL REGISTRATION NUMBER: clinicaltrials.gov NCT04141579.